{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Bioequivalence&page=33", "query": { "condition": "Bioequivalence", "page": 33 }, "page_size": 10 }, "pagination": { "page": 33, "page_size": 10, "total_count": 783, "total_pages": 79, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Bioequivalence&page=34&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Bioequivalence&page=32&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-25T00:06:38.884Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00649259", "title": "Food Study of Oxybutynin Chloride ER Tablets 10 mg and Ditropan XL® Tablets 10 mg", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Oxybutynin Chloride ER Tablets 10 mg", "type": "DRUG" }, { "name": "Ditropan XL® Tablets 10 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mylan Pharmaceuticals Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2002-10", "completion_date": "2002-11", "has_results": false, "last_update_posted_date": "2024-04-24", "last_synced_at": "2026-10-25T00:06:38.884Z", "location_count": 1, "location_summary": "Morgantown, West Virginia", "locations": [ { "city": "Morgantown", "state": "West Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00649259" }, { "nct_id": "NCT00649623", "title": "Fasting Study of Olmesartan Medoxomil Tablets 40 mg and Benicar® Tablets 40 mg", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Olmesartan Medoxomil Tablets 40 mg", "type": "DRUG" }, { "name": "Benicar® Tablets 40 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mylan Pharmaceuticals Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2005-12", "completion_date": "2005-12", "has_results": false, "last_update_posted_date": "2024-04-23", "last_synced_at": "2026-10-25T00:06:38.884Z", "location_count": 1, "location_summary": "Fargo, North Dakota", "locations": [ { "city": "Fargo", "state": "North Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00649623" }, { "nct_id": "NCT00649779", "title": "Fasting Study of Albuterol Sulfate Extended-Release Tablets 8 mg and VoSpire® ER Tablets 8 mg", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "albuterol sulfate extended-release 8 mg tablets", "type": "DRUG" }, { "name": "VoSpire™ ER 8 mg tablets", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mylan Pharmaceuticals Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2005-09", "completion_date": "2005-10", "has_results": false, "last_update_posted_date": "2008-04-01", "last_synced_at": "2026-10-25T00:06:38.884Z", "location_count": 1, "location_summary": "Fargo, North Dakota", "locations": [ { "city": "Fargo", "state": "North Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00649779" }, { "nct_id": "NCT03499873", "title": "Clinical Endpoint Study of Nepafenac 0.3% Opthalmic Suspension", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cataract" ], "interventions": [ { "name": "Nepafenac 0.3% Oph Susp", "type": "DRUG" }, { "name": "Placebos", "type": "DRUG" }, { "name": "Nepafenac 0.3% Oph Susp (reference)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Actavis Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 448, "start_date": "2018-03-28", "completion_date": "2018-12-18", "has_results": true, "last_update_posted_date": "2021-02-16", "last_synced_at": "2026-10-25T00:06:38.884Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03499873" }, { "nct_id": "NCT00352066", "title": "Pharmacokinetics of Apricitabine and Tipranavir When Dosed Alone or Together", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infection" ], "interventions": [ { "name": "apricitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Avexa", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "40 Years", "sex": "MALE", "summary": "18 Years to 40 Years · Male only" }, "enrollment_count": 18, "start_date": "2006-07", "completion_date": "2006-08", "has_results": false, "last_update_posted_date": "2011-06-23", "last_synced_at": "2026-10-25T00:06:38.884Z", "location_count": 1, "location_summary": "Kalamazoo, Michigan", "locations": [ { "city": "Kalamazoo", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00352066" }, { "nct_id": "NCT00648401", "title": "Food Study of Verapamil HCl Extended-Release Capsules 300 mg and Verelan® PM Extended-Release Capsules 300 mg", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Verapamil Hydrochloride Extended-Release Capsules, 300 mg", "type": "DRUG" }, { "name": "Verelan® PM Extended-Release Capsules, 300 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mylan Pharmaceuticals Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2006-01", "completion_date": "2006-02", "has_results": false, "last_update_posted_date": "2024-04-24", "last_synced_at": "2026-10-25T00:06:38.884Z", "location_count": 1, "location_summary": "Fargo, North Dakota", "locations": [ { "city": "Fargo", "state": "North Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00648401" }, { "nct_id": "NCT00830336", "title": "A Relative Bioavailability Study of 200mg/5 mL Azithromycin Oral Suspension Under Non-Fasting Conditions", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Azithromycin", "type": "DRUG" }, { "name": "Zithromax®", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Teva Pharmaceuticals USA", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2005-10", "completion_date": "2005-11", "has_results": true, "last_update_posted_date": "2024-08-20", "last_synced_at": "2026-10-25T00:06:38.884Z", "location_count": 1, "location_summary": "Fargo, North Dakota", "locations": [ { "city": "Fargo", "state": "North Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00830336" }, { "nct_id": "NCT06418607", "title": "A Study of the Safety, Tolerability, and Bioequivalence of Orally Administered Venglustat in Healthy Adult Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "Venglustat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 65, "start_date": "2020-06-23", "completion_date": "2020-07-13", "has_results": false, "last_update_posted_date": "2024-05-17", "last_synced_at": "2026-10-25T00:06:38.884Z", "location_count": 2, "location_summary": "Miami, Florida • Saint Paul, Minnesota", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Saint Paul", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06418607" }, { "nct_id": "NCT00829868", "title": "Zaleplon 10 mg Capsules Under Non-Fasting Conditions", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Zaleplon 10 mg Capsules", "type": "DRUG" }, { "name": "SONATA® 10 mg capsules", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Teva Pharmaceuticals USA", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2004-02", "completion_date": "2004-03", "has_results": true, "last_update_posted_date": "2024-08-21", "last_synced_at": "2026-10-25T00:06:38.884Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00829868" }, { "nct_id": "NCT03657290", "title": "A Study in Evaluating Bioequivalence of Test and Reference Vadadustat 450 MG and 150 MG Tablets and to Determine Food Effect on the 450 MG Tablet", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "vadadustat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Akebia Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 54, "start_date": "2018-08-03", "completion_date": "2018-10-16", "has_results": false, "last_update_posted_date": "2019-03-22", "last_synced_at": "2026-10-25T00:06:38.884Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03657290" } ] }